Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Indflydelsen af den henvisende laeges kliniske vurdering på ventetidsgarantien for brystkraeft i Frederiksborg Amt
Engelsk titel: The influence of the referring physician's clinical evaluation on the waiting time guarantee for breast cancer in the county of Frederiksborg Läs online Författare: Hoffmann J Språk: Dan Antal referenser: 11 Dokumenttyp: Artikel UI-nummer: 05051908

Tidskrift

Ugeskrift for Laeger 2005;167(22)2409-12 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Introduction: In 2000, the Danish Ministry of Health introduced a waiting time guarantee for breast cancer. All women suspected of having breast cancer must be called in for evaluation in a specialist clinic within 14 days. It was considered relevant to assess whether the guarantee is functioning according to plan. Materials and methods: A prospective registration of the referring doctors' referral pattern was carried out during a four-month period. The following data were registered: referral diagnosis, final diagnosis and waiting time from referral to assessment at the clinic. Results: During the period, 1,829 women were referred to the specialist clinic. In 90 women, the referral diagnosis was "suspicion of cancer"; 38 (42.2%) of these proved to have cancer. In 534 women, the referral diagnosis was a non-suspicious lump, bloody or clear nipple discharge or skin or nipple changes; 58 (10.9%) of these proved to have cancer. Amongst women referred with fibroadenomatosis, palpable lymph nodes or non-bloody or turbid nipple discharge, the incidence of cancer was 7 of 208 (3.4%). The waiting time guarantee for women referred with suspicion of cancer was fulfilled in 100% of the cases. The mean waiting time was five days. Discussion: It was logistically possible to fulfill the waiting time guarantee in 100% of the cases. However, the guarantee's guidelines "caught" only 31% of the women with breast cancer. If one were to expand the guarantee's inclusion criteria to encompass all women with palpable lumps, bloody or clear nipple discharge and skin or nipple changes, close to 80% of women with breast cancer would be covered by the guarantee.